The Role of GABA Receptors in Anesthesia and Sedation: An Updated Review.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
27 Oct 2024
27 Oct 2024
Historique:
accepted:
18
09
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
aheadofprint
Résumé
GABA (γ-aminobutyric acid) receptors are constituents of many inhibitory synapses within the central nervous system. They are formed by 5 subunits out of 19 various subunits: α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-3. Two main subtypes of GABA receptors have been identified, namely GABAA and GABAB. The GABAA receptor (GABAAR) is formed by a variety of combinations of five subunits, although both α and β subunits must be included to produce a GABA-gated ion channel. Other subunits are γ, δ, ε, π, and ϴ. GABAAR has many isoforms, that dictate, among other properties, their differing affinities and conductance. Drugs acting on GABAAR form the cornerstone of anesthesia and sedation practice. Some such GABAAR agonists used in anesthesia practice are propofol, etomidate, methohexital, thiopental, isoflurane, sevoflurane, and desflurane. Ketamine, nitrous oxide, and xenon are not GABAR agonists and instead inhibit glutamate receptors-mainly NMDA receptors. Inspite of its many drawbacks such as pain in injection, quick and uncontrolled conversion from sedation to general anesthesia and dose-related cardiovascular depression, propofol remains the most popular GABAR agonist employed by anesthesia providers. In addition, being formulated in a lipid emulsion, contamination and bacterial growth is possible. Literature is rife with newer propofol formulations, aiming to address many of these drawbacks, and with some degree of success. A nonemulsion propofol formulation has been developed with cyclodextrins, which form inclusion complexes with drugs having lipophilic properties while maintaining aqueous solubility. Inhalational anesthetics are also GABA agonists. The binding sites are primarily located within α
Identifiants
pubmed: 39465449
doi: 10.1007/s40263-024-01128-6
pii: 10.1007/s40263-024-01128-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Simeone TA, Donevan SD, Rho JM. Molecular biology and ontogeny of gamma-aminobutyric acid (GABA) receptors in the mammalian central nervous system. J Child Neurol. 2003;18:39–48 (discussion 49).
pubmed: 12661937
doi: 10.1177/08830738030180012101
Ramamoorthi K, Lin Y. The contribution of GABAergic dysfunction to neurodevelopmental disorders. Trends Mol Med. 2011;17:452–62.
pubmed: 21514225
pmcid: 3152662
doi: 10.1016/j.molmed.2011.03.003
Korpi ER, Sinkkonen ST. GABA(A) receptor subtypes as targets for neuropsychiatric drug development. Pharmacol Ther. 2006;109:12–32.
pubmed: 15996746
doi: 10.1016/j.pharmthera.2005.05.009
Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev. 2004;84:835–67.
pubmed: 15269338
doi: 10.1152/physrev.00036.2003
Nutt D. GABAA receptors: subtypes, regional distribution, and function. J Clin Sleep Med. 2006;2(2):S7-11.
pubmed: 17557501
doi: 10.5664/jcsm.26525
Whiting PJ. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today. 2003;8:445–50.
pubmed: 12801796
doi: 10.1016/S1359-6446(03)02703-X
Antkowiak B, Kirschfeld K. Neural mechanisms of anaesthesia [in German]. Anasthesiol Intensivmed. 2000;35:731–43.
doi: 10.1055/s-2000-8935
Collins JG, Kendig JJ, Mason P. Anesthetic actions within the spinal cord: contributions to the state of general anaesthesia. Trends Neurosci. 1995;18:549–53.
pubmed: 8638296
doi: 10.1016/0166-2236(95)98377-B
McGaugh JL, Izquierdo I. The contribution of pharmacology to research on the mechanisms of memory formation. Trends Pharmacol Sci. 2000;21:208–10.
pubmed: 10838606
doi: 10.1016/S0165-6147(00)01473-5
McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 2000;3:587–92.
pubmed: 10816315
doi: 10.1038/75761
Low K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 2000;290:131–4.
pubmed: 11021797
doi: 10.1126/science.290.5489.131
Chen K, Li HZ, Ye N, Zhang J, Wang JJ. Role of GABAB receptors in GABA and baclofen-induced inhibition of adult rat cerebellar interpositus nucleus neurons in vitro. Brain Res Bull. 2005;67(4):310–8.
pubmed: 16182939
doi: 10.1016/j.brainresbull.2005.07.004
Dimitrijevic N, Dzitoyeva S, Satta R, et al. Drosophila GABA(B) receptors are involved in behavioral effects of gamma-hydroxybutyric acid (GHB). Eur J Pharmacol. 2005;519(3):246–52.
pubmed: 16129424
doi: 10.1016/j.ejphar.2005.07.016
Dzitoyeva S, Dimitrijevic N, Manev H. Gamma-aminobutyric acid B receptor 1 mediates behavior-impairing actions of alcohol in Drosophila: adult RNA interference and pharmacological evidence. Proc Natl Acad Sci USA. 2003;100(9):5485–90.
pubmed: 12692303
pmcid: 154371
doi: 10.1073/pnas.0830111100
Manev H, Dimitrijevic N. Drosophila model for in vivo pharmacological analgesia research. Eur J Pharmacol. 2004;491(2–3):207–8.
pubmed: 15140638
doi: 10.1016/j.ejphar.2004.03.030
Brogden RN, Speight TM, Avery GS. Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity. Drugs. 1974;8(1):1–14.
pubmed: 4154834
doi: 10.2165/00003495-197408010-00001
Alkire MT, Hudetz AG, Tononi G. Consciousness and anesthesia. Science. 2008;322:876–80.
pubmed: 18988836
pmcid: 2743249
doi: 10.1126/science.1149213
Franks NP, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. Nature. 1994;367:607–14.
pubmed: 7509043
doi: 10.1038/367607a0
Sanna E, Garau F, Harris RA. Novel properties of homomeric beta 1 gamma-aminobutyric acid type A receptors: actions of the anaesthetics propofol and pentobarbital. Mol Pharmacol. 1995;47:213–7.
pubmed: 7870027
Jones MV, Harrison NL, Pritchett DB, Hales TG. Modulation of the GABAA receptor by propofol is independent of the gamma subunit. J Pharmacol Exp Ther. 1995;274:962–8.
pubmed: 7636760
Lam DW, Reynolds JN. Modulatory and direct effects of propofol on recombinant GABAA receptors expressed in xenopus oocytes: influence of alpha- and gamma2-subunits. Brain Res. 1998;784:179–87.
pubmed: 9518600
doi: 10.1016/S0006-8993(97)01334-6
Sanna E, Murgia A, Casula A, Biggio G. Differential subunit dependence of the actions of the general anaesthetics alphaxalone and etomidate at gamma-aminobutyric acid type A receptors expressed in Xenopus laevis oocytes. Mol Pharmacol. 1997;51:484–90.
pubmed: 9058604
Kay B, Rolly G. I.C.I. 35868, a new intravenous induction agent. Acta Anaesthesiol Belg. 1977;28:303–16.
pubmed: 613708
Chen S, Rex D. Registered nurse-administered propofol sedation for endoscopy. Aliment Pharmacol Ther. 2004;19(147):55.
Ansley DM, Raedschelders K, Choi PT, et al. Propofol cardioprotection for on-pump aortocoronary bypass surgery in patients with type 2 diabetes mellitus (PRO-TECT II): a phase 2 randomized-controlled trial. Can J Anesth. 2016;63:442–53.
pubmed: 26721648
doi: 10.1007/s12630-015-0580-z
De Cosmo G, Cancelli I, Adduci A, et al. Changes in the hemodynamics during isoflurane and propofol anaesthesia: a comparative study. Neurol Res. 2005;27:433–5.
pubmed: 15949243
doi: 10.1179/016164105X21724
Johnston A, Steiner L, Chatfield D, et al. Effects of propofol on cerebral oxygenation and metabolism after head injury. Br J Anaesth. 2003;91(6):781–6.
pubmed: 14633744
doi: 10.1093/bja/aeg256
Absalom AR, Struys M. An overview of TCI and TIVA. Ghent: Academia Press; 2005.
Aglio L, Lekowski R, Urman R. Essential clinical anaesthesia review. Cambridge: Cambridge University Press; 2015.
Russell D, Wilkes MP, Hunter SC, et al. Manual compared with target-controlled infusion of propofol. Br J Anaesth. 1995;75:562–6.
pubmed: 7577281
doi: 10.1093/bja/75.5.562
Absalom A, Kenny G. Closed-loop control of propofol anaesthesia using bispectral index: performance assessment in patients receiving computer-controlled propofol and manually controlled remifentanil infusions for minor surgery. B J Anaesth. 2003;90(6):737–41.
doi: 10.1093/bja/aeg137
Leslie K, Clavisi O, Hargrove J. Target-controlled infusion versus manually-controlled infusion of propofol for general anaesthesia or sedation in adults. Cochrane Database Syst Rev. 2008;3:CD006059.
Enlund M, Berglund A, Enlund A, et al. Impact of general anaesthesia on breast cancer survival: a 5-year follow up of a pragmatic, randomised, controlled trial, the CAN-study, comparing propofol and sevoflurane. EClinicalMedicine. 2023;60:102037. https://doi.org/10.1016/j.eclinm.2023.102037 . (Published 2023 Jun 9).
doi: 10.1016/j.eclinm.2023.102037
pubmed: 37333664
pmcid: 10276257
Cao SJ, Zhang Y, Zhang YX, et al. Long-term survival in older patients given propofol or sevoflurane anaesthesia for major cancer surgery: follow-up of a multicentre randomised trial. Br J Anaesth. 2023;131(2):266–75. https://doi.org/10.1016/j.bja.2023.01.023 .
doi: 10.1016/j.bja.2023.01.023
pubmed: 37474242
Gu L, Pan X, Wang C, Wang L. The benefits of propofol on cancer treatment: decipher its modulation code to immunocytes. Front Pharmacol. 2022;13: 919636.
pubmed: 36408275
pmcid: 9672338
doi: 10.3389/fphar.2022.919636
Chen F, Li M, Zhu X. Propofol suppresses proliferation and migration of papillary thyroid cancer cells by down-regulation of lncRNA ANRIL. Exp Mol Pathol. 2019;107:68–76.
pubmed: 30703346
doi: 10.1016/j.yexmp.2019.01.011
Bennett-Guerrero E, Romeiser JL, DeMaria S, et al. General Anesthetics in CAncer REsection Surgery (GA-CARES) randomized multicenter trial of propofol vs volatile inhalational anesthesia: protocol description. Perioper Med (Lond). 2023;12(1):2. https://doi.org/10.1186/s13741-022-00290-z . (Published 2023 Jan 11).
doi: 10.1186/s13741-022-00290-z
pubmed: 36631831
pmcid: 9832634
Cigognini B. Melbourne Medical School. 2022 [cited 2024 Sep 9]. VAPOR-C Trial. https://medicine.unimelb.edu.au/research-groups/critical-care-research/critcare/appmu/vapor-c .
Bachmann-Mennanga B, Ohlmer A, Heesen M. Incidence of pain after intravenous injection of a medium-/long-chain triglyceride emulsion of propofol. An observational study in 1375 patients. Arzneimittelforschung. 2003;53:621–6.
Fischer MJ, Leffler A, Niedermirtl F, et al. The general anaesthetic propofol excites nociceptors by activating TRPV1 and TRPA1 rather than GABAA receptors. J Biol Chem. 2010;285:34781–92.
pubmed: 20826794
pmcid: 2966094
doi: 10.1074/jbc.M110.143958
Ebert TJ. Sympathetic and hemodynamic effects of moderate and deep sedation with propofol in humans. Anesthesiology. 2005;103:20–4.
pubmed: 15983452
doi: 10.1097/00000542-200507000-00007
Blouin RT, Seifert HA, Babenco HD, et al. Propofol depresses the hypoxic ventilator response during conscious sedation and isohypercapnia. Anesthesiology. 1993;79:1177–82.
pubmed: 8267192
doi: 10.1097/00000542-199312000-00007
Nieuwenhuijs D, Sarton E, Teppema LJ, Dahan A. Propofol for monitored anaesthesia care: implications on hypoxic control of cardiorespiratory responses. Anesthesiology. 2000;92:46–54.
pubmed: 10638898
doi: 10.1097/00000542-200001000-00013
Bray RJ. Propofol infusion syndrome in children. Paediatr Anaesth. 1998;8:491–9.
pubmed: 9836214
doi: 10.1046/j.1460-9592.1998.00282.x
Kam PCA, Cardone D. Propofol infusion syndrome. Anaesthesia. 2007;62:690–701.
pubmed: 17567345
doi: 10.1111/j.1365-2044.2007.05055.x
Wachowski I, Jolly DT, Hrazdil J, et al. The growth of microorganisms in propofol and mixtures of propofol and lidocaine. Anesth Analg. 1999;88:209–12.
pubmed: 9895094
doi: 10.1213/00000539-199901000-00039
McHugh GJ, Roper GM. Propofol emulsion and bacterial contamination. Can J Anaesth. 1995;42:801–4.
pubmed: 7497562
doi: 10.1007/BF03011181
Langevin PB, Gravenstein N, Doyle TJ, et al. Growth of Staphylococcus aureus in diprivan and intralipid implications on the pathogenesis of infection. Anesthesiology. 1999;91:1394–400.
pubmed: 10551591
doi: 10.1097/00000542-199911000-00032
Feng AY, Kaye AD, Kaye RJ, Belani K, Urman RD. Novel propofol derivatives and implications for anaesthesia practice. J Anaesthesiol Clin Pharmacol. 2017;33(1):9–15. https://doi.org/10.4103/0970-9185.202205 .
doi: 10.4103/0970-9185.202205
pubmed: 28413268
pmcid: 5374837
Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology. 2005;103:860–76.
pubmed: 16192780
doi: 10.1097/00000542-200510000-00026
Lu M, Liu J, Wu X, Zhang Z. Ciprofol: a novel alternative to propofol in clinical intravenous anesthesia? Biomed Res Int. 2023;19(2023):7443226. https://doi.org/10.1155/2023/7443226 .
doi: 10.1155/2023/7443226
Damitz R, Chauhan A. “Micro to macro (M2M)”—a novel approach for intravenous delivery of propofol. Int J Pharm. 2015;494:218–26.
pubmed: 26260228
doi: 10.1016/j.ijpharm.2015.08.018
Traul KA, Driedger A, Ingle DL, Nakhasi D. Review of the toxicologic properties of medium-chain triglycerides. Food Chem Toxicol. 2000;38:79–98.
pubmed: 10685018
doi: 10.1016/S0278-6915(99)00106-4
Larsen R, Beerhalter U, Erdkönig R, Larsen B. Injection pain from propofol-MCT-LCT in children. A comparison with propofol-LCT. Anaesthesist. 2001;50:676–8.
pubmed: 11593871
doi: 10.1007/s001010100213
Doenicke AW, Roizen MF, Rau J, O’Connor M, Kugler J, Klotz U, et al. Pharmacokinetics and pharmacodynamics of propofol in a new solvent. Anesth Analg. 1997;85:1399–403.
pubmed: 9390616
doi: 10.1213/00000539-199712000-00040
Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci. 1997;86:147–62.
pubmed: 9040088
doi: 10.1021/js960213f
Melton MS, Nielsen KC, Tucker M, Klein SM, Gan TJ. New medications and techniques in ambulatory anaesthesia. Anesthesiol Clin. 2014;32:463–85.
pubmed: 24882131
doi: 10.1016/j.anclin.2014.02.003
Wallentine CB, Shimode N, Egan TD, Pace NL. Propofol in a modified cyclodextrin formulation: First human study of dose-response with emphasis on injection pain. AnesthAnalg. 2011;113:738.
Ravenelle F, Vachon P, Rigby-Jones AE, Sneyd JR, Le Garrec D, Gori S, et al. Anaesthetic effects of propofol polymeric micelle: a novel water soluble propofol formulation. Br JAnaesth. 2008;101:186–93.
doi: 10.1093/bja/aen147
Levitzky BE, Vargo JJ. Fospropofol disodium injection for the sedation of patients undergoing colonoscopy. Ther Clin Risk Manag. 2008;4(4):733–8. https://doi.org/10.2147/tcrm.s3091 .
doi: 10.2147/tcrm.s3091
pubmed: 19209255
pmcid: 2621391
Lei L, Liu J. Respiratory and cardiovascular safety of HX0507 in beagle dogs. Anesthesiology. 2007;107:A1102.
Yang J, Yin W, Liu J, Wang Y, Zhou C, Kang Y, et al. Synthesis and characterization of novel quick-release propofol prodrug via lactonization. Bioorg Med Chem Lett. 2013;23:1813–6.
pubmed: 23395634
doi: 10.1016/j.bmcl.2013.01.034
Siegel LC, Pelc LR, Shaff K. Dose response of PF0713, a novel investigational intravenous anaesthetic agent. Anesthesiology. 2008;109:A869.
Lundy JS. Intravenous anaesthesia: preliminary report of the use of two new thiobarbiturates. Proc Mayo Clin. 1935;10:536–43.
Chernish SM, Gruber CM, Demeyer M, Littlefield S, Stoeling VK. Double blind comparison of compound 22451, pentothal and surital. Fed Proc. 1956;15:409.
Hooten WM, Rasmussen KG. Effects of general anaesthetic agents in adults receiving electroconvulsive therapy: a systematic review. J ECT. 2008;24:208–23.
pubmed: 18628717
doi: 10.1097/YCT.0b013e31815bfe2a
Steinbach JH, Akk G. Modulation of GABA(A) receptor channel gating by pentobarbital. J Physiol. 2001;537:715–33.
pubmed: 11744750
pmcid: 2278986
doi: 10.1113/jphysiol.2001.012818
Drafts BC, Fisher JL. Identification of structures within GABAA receptor alpha subunits that regulate the agonist action of pentobarbital. J Pharmacol Exp Ther. 2006;318:1094–101.
pubmed: 16728592
doi: 10.1124/jpet.106.104844
Bieda MC, Su H, Maciver MB. Anesthetics discriminate between tonic and phasic gamma-aminobutyric acid receptors on hippocampal CA1 neurons. Anesth Analg. 2009;108:484–90.
pubmed: 19151276
pmcid: 2630469
doi: 10.1213/ane.0b013e3181904571
Oddo M, Crippa I, Mehta S, et al. Optimizing sedation in patients with acute brain injury. Crit Care. 2016;20:128.
pubmed: 27145814
pmcid: 4857238
doi: 10.1186/s13054-016-1294-5
Ioannides C, Parke DV. Mechanism of induction of hepatic microsomal drug metabolizing enzymes by a series of barbiturates. J Pharm Pharmacol. 1975;27(10):739–46.
pubmed: 241786
doi: 10.1111/j.2042-7158.1975.tb09393.x
Christensen JH, Andreasen F, Jansen J. Pharmacokinetics and pharmacodynamics of thiopental in patients undergoing renal transplantation. Acta Anaesthesiol Scand. 1983;27(6):513–8.
pubmed: 6364679
doi: 10.1111/j.1399-6576.1983.tb01998.x
Dundee JW, McCleery WN, McLoughlin G. The hazard of thiopental anaesthesia in porphyria. Anesth Analg. 1962;41:567–74.
pubmed: 13888459
doi: 10.1213/00000539-196209000-00013
Thiopental summary of product characteristics. https://www.medicines.org.uk/emc/medicine/14338 . Accessed 5 Apr 2024.
Cordato DJ, Herkes GK, Mather LE, et al. Prolonged thiopentone infusion for neurosurgical emergencies: usefulness of therapeutic drug monitoring. Anaesth Intensive Care. 2001;29(4):339–48.
pubmed: 11512643
doi: 10.1177/0310057X0102900403
Godefroi EF, Jansen PA, Ven Der Eychen CA, et al. DL-1-(1-Arylalkyl)imidazole-5-carboxylate esters: a novel type of hypotic agents. J Med Chem. 1965;8:220–3.
pubmed: 14332665
doi: 10.1021/jm00326a017
Doenicke A. Etomidate, a new intravenous hypnotic. Acta Anaesthesiol Belg. 1974;25(3):307–15.
pubmed: 4143092
Janssen PA, Niemegeers CJ, Marsboom RP. Etomidate, a potent non-barbiturate hypnotic. Intravenous etomidate in mice, rats, guinea pigs, rabbits and dogs. Arch Int Pharmacodyn Ther. 1975;214:92–132.
pubmed: 1156027
Gurgel do Amaral Valente Sá L, da Silva CR, Neto JBA, et al. Antifungal activity of etomidate against growing biofilms of fluconazole-resistant Candida spp. strains, binding to mannoproteins and molecular docking with the ALS3 protein. J Med Microbiol. 2020;69(10):1221–7. https://doi.org/10.1099/jmm.0.001241 .
doi: 10.1099/jmm.0.001241
pubmed: 32894212
do Av Sá LG, da Silva CR, Campos RS, et al. Synergistic anticandidal activity of etomidate and azoles against clinical fluconazole-resistant Candida isolates. Future Microbiol. 2019;14:1477–88. https://doi.org/10.2217/fmb-2019-0075 .
doi: 10.2217/fmb-2019-0075
pubmed: 31916846
Thyagarajan R, Ramanjaneyulu R, Ticku MK. Enhancement of diazepam and gamma-aminobutyric acid binding by etomidate and pentobarbital. J Neurochem. 1983;41:578–85.
pubmed: 6308164
doi: 10.1111/j.1471-4159.1983.tb04778.x
Li GD, Chiara DC, Sawyer GW, Husain SS, Olsen RW, Cohen JB. Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. J Neurosci. 2006;26:11599–605. https://doi.org/10.1523/JNEUROSCI.3467-06.2006 .
doi: 10.1523/JNEUROSCI.3467-06.2006
pubmed: 17093081
pmcid: 6674783
Jurd R, Arras M, Lambert S, Drexler B, Siegwart R, Crestani F, et al. General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit. FASEB J. 2003;17:250–2. https://doi.org/10.1096/fj.02-0611 .
doi: 10.1096/fj.02-0611
pubmed: 12475885
Weir CJ, Mitchell SJ, Lambert JJ. Role of GABA A receptor subtypes in the behavioural effects of intravenous general anaesthetics. Br J Anaesth. 2017;119:i167–75. https://doi.org/10.1093/bja/aex369 .
doi: 10.1093/bja/aex369
pubmed: 29161398
Valk BI, Absalom AR, Meyer P, Meier S, den Daas I, van Amsterdam K, Campagna JA, Sweeney SP, Struys MMRF. Safety and clinical effect of i.v. infusion of cyclopropyl-methoxycarbonyl etomidate (ABP-700), a soft analogue of etomidate, in healthy subjects. Br J Anaesth. 2018;120(6):1401–11. https://doi.org/10.1016/j.bja.2018.01.038 .
doi: 10.1016/j.bja.2018.01.038
pubmed: 29793605
Valk BI, Struys MMRF. Etomidate and its analogs: a review of pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2021;60(10):1253–69. https://doi.org/10.1007/s40262-021-01038-6 . (Epub 2021 Jun 1).
doi: 10.1007/s40262-021-01038-6
pubmed: 34060021
pmcid: 8505283
Hill-Venning C, Belelli D, Peters JA, Lambert JJ. Subunit-dependent interaction of the general anaesthetic etomidate with the gamma- aminobutyric acid type A receptor. Br J Pharmacol. 1997;120:749–56.
pubmed: 9138677
pmcid: 1564523
doi: 10.1038/sj.bjp.0700927
Uchida I, Kamatchi G, Burt D, Yang J. Etomidate potentiation of GABAA receptor gated current depends on the subunit composition. Neurosci Lett. 1995;185:203–6.
pubmed: 7753491
doi: 10.1016/0304-3940(95)11263-V
Gooding JM, Corssen G. Effect of etomidate on the cardiovascular system. Anesth Analg. 1977;56:717–9.
pubmed: 562099
doi: 10.1213/00000539-197709000-00021
Mohr NM, Pape SG, Runde D, Kaji AH, Walls RM, Brown CA 3rd. Etomidate use is associated with less hypotension than ketamine for emergency department sepsis intubations: a NEAR cohort study. Acad Emerg Med. 2020;27(11):1140–9. https://doi.org/10.1111/acem.14070 .
doi: 10.1111/acem.14070
pubmed: 32602974
pmcid: 8711033
Lallemand MA, Lentschener C, Mazoit JX, Bonnichon P, Manceau I, Ozier Y. Bispectral index changes following etomidate induction of general anaesthesia and orotracheal intubation. Br J Anaesth. 2003;91:341–6.
pubmed: 12925471
doi: 10.1093/bja/aeg175
Kuizenga K, Wierda JMKH, Kalkman CJ. Biphasic EEG changes in relation to loss of consciousness during induction with thiopental, propofol, etomidate, midazolam or sevoflurane. Br J Anaesth. 2001;86:354–60.
pubmed: 11573524
doi: 10.1093/bja/86.3.354
Yelavich PM, Holmes CM. Etomidate: a foreshortened clinical trial. Anaesth Intensive Care. 1980;8:479–83.
pubmed: 7457821
doi: 10.1177/0310057X8000800417
Meinck HM, Möhlenhof O, Kettler D. Neurophysiological effects of etomidate, a new short-acting hypnotic. Electroencephalogr Clin Neurophysiol. 1980;50:515–22.
pubmed: 6160995
doi: 10.1016/0013-4694(80)90019-X
Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet. 1983;321:1270.
doi: 10.1016/S0140-6736(83)92712-5
Watt I, Ledingham IM. Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia. 1984;39:973.
pubmed: 6496912
doi: 10.1111/j.1365-2044.1984.tb08885.x
Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anaesthetic etomidate. N Engl J Med. 1984;310:1415–21.
pubmed: 6325910
doi: 10.1056/NEJM198405313102202
Wagner RL, White PF. Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology. 1984;61:647–51.
pubmed: 6095700
doi: 10.1097/00000542-198412000-00003
Jackson WL. Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock? A critical appraisal. Chest. 2005;127:1031–8.
pubmed: 15764790
doi: 10.1378/chest.127.3.1031
Walls RM, Murphy MF. Clinical controversies: etomidate as an induction agent for endotracheal intubation in patients with sepsis: continue to use etomidate for intubation of patients with septic shock. Ann Emerg Med. 2008;52:13–4.
pubmed: 18565378
doi: 10.1016/j.annemergmed.2008.01.344
Allolio B, Stuttmann R, Leonhard U, Fischer H, Winkelmann W. Adrenocortical suppression by a single induction dose of etomidate. Klin Wochenschr. 1984;62:1014–7.
pubmed: 6096626
doi: 10.1007/BF01711723
Fragen RJ, Shanks CA, Molteni A, Avram MJ. Effects of etomidate on hormonal responses to surgical stress. Anesthesiology. 1984;61:652–6.
pubmed: 6095701
doi: 10.1097/00000542-198412000-00004
Hildreth AN, Mejia VA, Maxwell RA, Smith PW, Dart BW, Barker DE. Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study. J Trauma. 2008;65(3):573–9. https://doi.org/10.1097/TA.0b013e31818255e8 .
doi: 10.1097/TA.0b013e31818255e8
pubmed: 18784570
Wannscher M, Tonessen E, Hüttel M, Larsen K. Etomidate infusion and adrenocortical function: a study in elective surgery. Acta Anaesthesiol Scand. 1985;29:483–5.
doi: 10.1111/j.1399-6576.1985.tb02238.x
Groth C, Acquista N, Khadem T. Current practices and safety of medication use during rapid sequence intubation (RSI). Crit Care Med. 2015;43(12):147.
doi: 10.1097/01.ccm.0000474410.93222.6b
Ball CM, Westhorpe RN. Intravenous induction agents: etomidate. Anaesth Intens Care. 2002;30(4):405.
doi: 10.1177/0310057X0203000401
Johnstone M. The human cardiovascular response to fluothane anaesthesia. Br J Anaesth. 1956;28:392.
pubmed: 13364102
doi: 10.1093/bja/28.9.392
Bovill JG. Inhalational anaesthesia: from diethyl ether to xenon. In: Schuttler J, Schwilden H, editors. Handbook of experimental pharmacology. Berlin: Springer; 2008. p. 122–42.
Smith I, Nathanson M, White PF. Sevoflurane—a long-awaited volatile anaesthesia. Br J Anaesth. 1996;76:435–45.
pubmed: 8785147
doi: 10.1093/bja/76.3.435
Eager MM, Nolan GS, Tonks K, Ramjeeawon A, Taylor N. Inhaled methoxyflurane (Penthrox) for analgesia in trauma: a systematic review protocol. Syst Rev. 2021;10(1):47. https://doi.org/10.1186/s13643-021-01600-0 . (Published 2021 Feb 3).
doi: 10.1186/s13643-021-01600-0
pubmed: 33536052
pmcid: 7860209
Martindale AE, Morris DS, Cromarty T, Fennell-Wells A, Duane B. Environmental impact of low-dose methoxyflurane versus nitrous oxide for analgesia: how green is the “green whistle”? Emerg Med J. 2024;41(2):69–75. https://doi.org/10.1136/emermed-2022-213042 . (Published 2024 Jan 22).
doi: 10.1136/emermed-2022-213042
pubmed: 37770121
Mihic SJ, Ye Q, Wick MJ, et al. Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature. 1997;389:385–9.
pubmed: 9311780
doi: 10.1038/38738
Jenkins A, Greenblatt EP, Faulkner HJ, et al. Evidence for a common binding cavity for three general anaesthetics within the GABAA receptor. J Neurosci. 2001;21(RC136):1–4.
Woll KA, Zhou X, Bhanu NV, Garcia BA, Covarrubias M, Miller KW, Eckenhoff RG. Identification of binding sites contributing to volatile anesthetic effects on GABA type A receptors. FASEB J. 2018;32(8):4172–89. https://doi.org/10.1096/fj.201701347R . (Epub 2018 Mar 5).
doi: 10.1096/fj.201701347R
pubmed: 29505303
pmcid: 6044061
Garcia PS, Kolesky SE, Jenkins A. General anaesthetic actions on GABAA receptors. Curr Neuropharmacol. 2010;8(1):2–9.
pubmed: 20808541
pmcid: 2866459
doi: 10.2174/157015910790909502
Wheeler DM, Katz A, Rice RT, Hansford RG. Volatile anaesthetic effects on sarcoplasmic reticulum calcium content and sarcolemmal calcium flux in isolated rat cardiac cell suspensions. Anesthesiology. 1994;80:372–82.
pubmed: 8311319
doi: 10.1097/00000542-199402000-00017
Meng T, Bu W, Ren X, et al. Molecular mechanism of anesthetic-induced depression of myocardial contraction. FASEB J. 2016;30(8):2915–25. https://doi.org/10.1096/fj.201600290RR .
doi: 10.1096/fj.201600290RR
pubmed: 27170289
pmcid: 5072354
Van den Elsen M, Sarton E, Teppema L, Berkenbosch A, Dahan A. Influence of 0.1 minimum alveolar concentration of sevoflurane, desflurane and isoflurane on dynamic ventilatory response to hypercapnia in humans. Br J Anaesth. 1998;80:174–82.
pubmed: 9602581
doi: 10.1093/bja/80.2.174
Rosenberg H, Pollock N, Schiemann A, et al. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93.
pubmed: 26238698
pmcid: 4524368
doi: 10.1186/s13023-015-0310-1
Kenna JG, van Pelt FN. The metabolism and toxicity of inhaled anaesthetic agents. Anaesth Pharmacol Rev. 1994;2:29–42.
Kim YH, Yoon SZ, Lim HJ, Yoon SM. Prophylactic use of midazolam or propofol at the end of surgery may reduce the incidence of emergence agitation after sevoflurane anaesthesia. Anaesth Intensive Care. 2011;39:904–8. https://doi.org/10.1177/0310057X1103900516 .
doi: 10.1177/0310057X1103900516
pubmed: 21970137
Vlajkovic GP, Sindjelic RP. Emergence delirium in children: many questions, few answers. Anesth Analg. 2007;104:84–91. https://doi.org/10.1213/01.ane.0000250914.91881.a8 .
doi: 10.1213/01.ane.0000250914.91881.a8
pubmed: 17179249
Mason KP. Paediatric emergence delirium: a comprehensive review and interpretation of the literature. Br J Anaesth. 2017;118:335–43. https://doi.org/10.1093/bja/aew477 .
doi: 10.1093/bja/aew477
pubmed: 28203739
Xiao Y, Jin X, Zhang Y, Huang T, Zhou L, Gao J. Efficacy of propofol for the prevention of emergence agitation after sevoflurane anaesthesia in children: a meta-analysis. Frontiers in Surgery. 2022;3(9):1031010.
doi: 10.3389/fsurg.2022.1031010
Yang X, Lin C, Chen S, Huang Y, Cheng Q, Yao Y. Remimazolam for the prevention of emergence delirium in children following tonsillectomy and adenoidectomy under sevoflurane anesthesia: a randomized controlled study. Drug Des Devel Ther. 2022;16:3413–20. https://doi.org/10.2147/DDDT.S381611 . (Published 2022 Sep 30).
doi: 10.2147/DDDT.S381611
pubmed: 36203819
pmcid: 9531607
Shi M, Miao S, Gu T, Wang D, Zhang H, Liu J. Dexmedetomidine for the prevention of emergence delirium and postoperative behavioral changes in pediatric patients with sevoflurane anesthesia: a double-blind, randomized trial. Drug Des Devel Ther. 2019;13:897–905. https://doi.org/10.2147/DDDT.S196075 . (Published 2019 Mar 15).
doi: 10.2147/DDDT.S196075
pubmed: 30936683
pmcid: 6421876
Page C, Hoffman BB, Curtis M. Integrated pharmacology. 3rd ed. Philadelphia: Mosby; 2006.
Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharm. 2008;182:335–60.
doi: 10.1007/978-3-540-74806-9_16
Cascade E, Kalali AH. Use of benzodiazepines in the treatment of anxiety. Psychiatry. 2008;5(9):21–2.
pubmed: 19727256
pmcid: 2687085
Kelly MD, Smith A, Banks G, et al. Role of the histidine residue at position 105 in the human alpha 5 containing GABA(A) receptor on the affinity and efficacy of benzodiazepine site ligands. Br J Pharmacol. 2002;135(1):248–56.
pubmed: 11786501
pmcid: 1573121
doi: 10.1038/sj.bjp.0704459
Sieghart W. Pharmacology of benzodiazepine receptors: an update. J Psychiatry Neurosci. 1994;19(1):24–9.
pubmed: 8148363
pmcid: 1188559
Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999;401(6755):796–800.
pubmed: 10548105
doi: 10.1038/44579
Kaufmann WA, Humpel C, Alheid GF, Marksteiner J. Compartmentation of alpha 1 and alpha 2 GABA(A) receptor subunits within rat extended amygdala: implications for benzodiazepine action. Brain Res. 2003;964(1):91–9.
pubmed: 12573516
doi: 10.1016/S0006-8993(02)04082-9
Crestani F, Löw K, Keist R, et al. Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol. 2001;59(3):442–5.
pubmed: 11179437
doi: 10.1124/mol.59.3.442
Sarasin DS, Ghoneim MM, Block RI. Effects of sedation with midazolam or propofol on cognition and psychomotor functions. J Oral Maxillofac Surg. 1996;54:1187–93.
pubmed: 8859237
doi: 10.1016/S0278-2391(96)90348-1
Kestin IG, Harvey PB, Nixon C. Psychomotor recovery after three methods of sedation during spinal anaesthesia. Br J Anaesth. 1990;64:675–8.
pubmed: 2116156
doi: 10.1093/bja/64.6.675
Ibrahim AE, Taraday JK, Kharasch ED. Bispectral index monitoring during sedation with sevoflurane, midazolam, and propofol. Anesthesiology. 2001;95:1151–9.
pubmed: 11684984
doi: 10.1097/00000542-200111000-00019
Parida S. Utility of BIS for sedation management during monitored anaesthesia care. Indian J Anaesth. 2010;54(3):263.
pubmed: 20885881
pmcid: 2933493
doi: 10.4103/0019-5049.65350
Gamble JA, Kawar P, Dundee JW, Moore J, Briggs LP. Evaluation of midazolam as an intravenous induction agent. Anaesthesia. 1981;36(9):868–73.
pubmed: 7304889
doi: 10.1111/j.1365-2044.1981.tb08859.x
Sear JW. Research into new drugs in anaesthesia: then and now. Anesth Analg. 2012;115(2):233–4.
pubmed: 22826523
doi: 10.1213/ANE.0b013e31825370a7
Buchwald P, Bodor N. Recent advances in the design and development of soft drugs. Pharmazie. 2014;69:403–13.
pubmed: 24974571
Lusedra US prescribing Information. http://medlibrary.org/lib/rx/meds/lusedra/ . Accessed 03 Apr 2024.
Lee M (MD), NYU Langone Medical Centre (US). Preventing propofol injection pain: prospective randomized trial comparing propofol versus fospropofol [ClinicalTrials.gov identifier NCT01401049]. 2015. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01401049 . Accessed 30 Mar 2022.
Welliver M, Rugari SM. New drug, fospropofol disodium: a propofol prodrug. AANA J. 2009;77(4):301–8.
pubmed: 19731849
Brohan J, Lee P. Newer drugs for sedation: soft pharmacology. In: Goudra BG, Singh PM, editors. Out of operating room anaesthesia: a comprehensive review. Cham: Springer; 2017.
Abdelmalak B, Khanna A, Tetzlaff J. Fospropofol, a new sedative anaesthetic, and its utility in the perioperative period. Curr Pharm Des. 2012;18(38):6241–52.
pubmed: 22762463
doi: 10.2174/138161212803832308
FDA approval of fospropofol. https://www.drugs.com/newdrugs/fda-approveslusedra-fospropofol-disodium monitored-anesthesiacare-mac-sedation-1205.html. Accessed 3 Apr 2024.
Mueller SW, Moore GD, MacLaren R. Fospropofol disodium for procedural sedation: emerging evidence of its value? Clin Med Insights Ther. 2010;2:513–22.
Candiotti KA, Gan TJ, Young C, et al. A randomized, open label study of the safety and tolerability of fospropofol for patients requiring intubation and mechanical ventilation in the intensive care unit. Anesth Analg. 2011;113(3):550–6.
pubmed: 21596879
doi: 10.1213/ANE.0b013e31821d7faf
Fechner J, Ihmsen H, Schuttler J, Jeleazcov C. A randomized open label phase I pilot study of the safety and efficacy of total intravenous anaesthesia with fospropofol for coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2013;27(5):908–15.
pubmed: 24054187
doi: 10.1053/j.jvca.2013.01.029
Zorrilla-Vaca A, Arevalo JJ, Escandoń-Vargas K, Soltanifar D, Mirski MA. Infectious disease risk associated with contaminated propofol anaesthesia, 1989–2014. Emerg Infect Dis. 2016;22(6):981–92.
pubmed: 27192163
pmcid: 4880094
doi: 10.3201/eid2206.150376
Struys M, Fechner J, Schuttler J, Schwilden H. Erroneously published fospropofol pharmacokinetic–pharmacodynamic data and retraction of the affected publications. Anesthesiology. 2010;112(4):1056–7.
pubmed: 20177373
doi: 10.1097/ALN.0b013e3181d536df
Rex DK, Cohen LB, Kline JK, et al. Fospropofol disodium for minimal-to-moderate sedation during colonoscopy produces clear-headed recovery: results of a phase 3, randomized, doubleblind trial. Gastrointest Endosc. 2007;65:AB367.
Cohen L, Cattau E, Goetch A, et al. A randomized, doubleblind, phase 3 study of fospropofol disodium for sedation during colonoscopy. J Clin Gastroent. 2010;44(5):345–53.
pubmed: 19996984
doi: 10.1097/MCG.0b013e3181c2987e
Silvestri GA, Vincent BD, Wahidi MM, et al. A phase 3, randomized, double-blind study to assess the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy. Chest. 2009;135(41):7.
Medscape. Fospropofol (discontinued). http://reference.medscape.com/drug/lusedra-fospropofol-343112 . Accessed 16 Mar 2024.
Cotten JF, Husain SS, Forman SA, et al. Methoxycarbonyletomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology. 2009;111:240–9.
pubmed: 19625798
doi: 10.1097/ALN.0b013e3181ae63d1
Cotton JF, Le Ge R, Banacos N, et al. Closed-loop continuous infusions of etomidate and etomidate analogs in rats: a comparative study of dosing and the impact on adrenocortical function. Anesthesiology. 2011;115:764–73.
doi: 10.1097/ALN.0b013e31821950de
Le Ge R, Pejo E, Haburcak M, et al. Pharmacological studies of methoxycarbonyl etomidate’s carboxylic acid metabolite. Anesth Analg. 2012;115(2):305–8.
pubmed: 22052979
doi: 10.1213/ANE.0b013e318239c6ca
Pejo E, Ge R, Banacos N, et al. Electroencephalographic recovery, hypnotic emergence, and the effects of metabolite after continuous infusions of a rapidly metabolized etomidate analog in rats. Anesthesiology. 2012;116:1057–65.
pubmed: 22417966
doi: 10.1097/ALN.0b013e3182515403
Husain SS, Pejo E, Ge R, et al. Modifying methoxycarbonyl etomidate inter-ester specer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of action. Anesthesiology. 2012;117(5):1027–36.
pubmed: 22929736
doi: 10.1097/ALN.0b013e31826d3bef
Ge R, Pejo E, Husain SS, et al. Encephalographic and hypnotic recoveries following brief and prolonged infusions of etomidate and optimized soft etomidate analogs. Anesthesiology. 2012;117:1037–43.
pubmed: 22929726
doi: 10.1097/ALN.0b013e31826d3de2
Pejo E, Liu J, Lin X, Raines DE. Distinct hypnotic recoveries after infusions of methoxycarbonyl etomidate and cyclopropyl methoxycarbonyl metomidate: the role of the metabolite. Anesth Analg. 2016;122(4):1008–14.
pubmed: 26991617
pmcid: 4800831
doi: 10.1213/ANE.0000000000001146
Ge R, Pejo E, Gallin H, Jeffrey S, Cotten JF, Raines DE. The pharmacology of cyclopropyl-methoxycarbonyl metomidate: a comparison with propofol. Anesth Analg. 2014;118:563–7. https://doi.org/10.1213/ANE.0000000000000069 .
doi: 10.1213/ANE.0000000000000069
pubmed: 24557104
pmcid: 6310170
Santer P, Pejo E, Feng Y, et al. Cyclopropyl-methoxycarbonyl metomidate: studies in a lipopolysaccharide inflammatory model of sepsis. Anesthesiology. 2015;123(2):368–76.
pubmed: 26035348
doi: 10.1097/ALN.0000000000000721
Struys MMRF, Valk BI, Eleveld DJ, et al. A phase 1, single center, double-blind, placebo-controlled study in healthy subjects to assess the safety, tolerability, clinical effects, and pharmacokinetics-pharmacodynamics of intravenous cyclopropyl- (ABP-700) after a single ascending bolus dose. Anesthesiology. 2017;127(1):20–35.
pubmed: 28459733
doi: 10.1097/ALN.0000000000001662
Pejo E, Cotton JF, Kelly EW, et al. In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate. Anesth Analg. 2012;115(2):297–304.
pubmed: 21965364
doi: 10.1213/ANE.0b013e3182320559
Cotten JF, Forman SA, Laha JK, et al. Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology. 2010;112:637–44.
pubmed: 20179500
doi: 10.1097/ALN.0b013e3181cf40ed
Wang B, Chen S, Yang J, Yang L, Liu J, Zhang W. ET-26 hydrochloride (ET-26 HCl) has similar hemodynamic stability to that of etomidate in normal and uncontrolled hemorrhagic shock(UHS) rats. PLoS ONE. 2017;12(8): e0183439.
pubmed: 28813523
pmcid: 5557577
doi: 10.1371/journal.pone.0183439
Wang B, Jiang J, Yang J, Chen J, Zhu Z, Liu J, et al. Pharmacologic studies on ET-26 hydrochloride in a rat model of lipopolysaccharide-induced sepsis. Eur J Pharm Sci. 2017;109:441–5.
pubmed: 28882766
doi: 10.1016/j.ejps.2017.09.005
Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology. 2007;107:60–6.
pubmed: 17585216
doi: 10.1097/01.anes.0000267503.85085.c0
Sneyd R. Remimazolam: new beginnings or just a me-too? Anesth Analg. 2012;115(2):217–9.
pubmed: 22826518
doi: 10.1213/ANE.0b013e31823acb95
Antonik LJ, Goldwater R, Kilpatrick GJ, et al. A placebo and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part I. Safety, efficacy and basic pharmacokinetics. Anesth Analg. 2012;115:274–83.
pubmed: 22190555
doi: 10.1213/ANE.0b013e31823f0c28
Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo and midazolam-controlled phase I single ascending dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056). Part II: pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012;115:284–96.
pubmed: 22253270
doi: 10.1213/ANE.0b013e318241f68a
Worthington MT, Antonik LJ, Goldwater DR, et al. A phase Ib dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesth Analg. 2013;117:1093–100.
pubmed: 24108261
doi: 10.1213/ANE.0b013e3182a705ae
Borkett KM, Riff DS, Schwartz HI, et al. A phase II, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth Analg. 2015;120(4):771–80.
pubmed: 25502841
doi: 10.1213/ANE.0000000000000548
Lee A, Shirley M. Remimazolam: a review in procedural sedation. Drugs. 2021;81(10):1193–201. https://doi.org/10.1007/s40265-021-01544-8 .
doi: 10.1007/s40265-021-01544-8
pubmed: 34196946
Pastis NJ, Yarmus LB, Schippers F, et al. Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest. 2019;155(1):137–46.
pubmed: 30292760
doi: 10.1016/j.chest.2018.09.015
Rex DK, Bhandari R, Desta T, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2018;88(3):427-37.e6.
pubmed: 29723512
doi: 10.1016/j.gie.2018.04.2351
Rex DK, Bhandari R, Lorch DG, et al. Safety and efficacy of remimazolam in high risk colonoscopy: a randomized trial. Dig Liver Dis. 2021;53:94–101.
pubmed: 33243567
doi: 10.1016/j.dld.2020.10.039
US Food and Drug Administration. 212295Orig1s000 clinical review(s) 2020. https://www.accessdata.fda.gov . Accessed 21 Mar 2024.
Acacia Pharma Inc. BYFAVO™ (remimazolam): US prescribing information. 2021. https://www.accessdata.fda.gov . Accessed 21 Mar 2024.
ClinicalTrials.gov. Search results: remimazolam. https://clinicaltrials.gov/ct2/results?term=remimazolam&Search=Search . Accessed 16 June 2017.
Cottrell GA, Lambert JJ, Peters JA. Modulation of the GABA receptor activity by alphaxalone. Br J Pharmacol. 1987;90:491–500.
pubmed: 3032320
pmcid: 1917172
doi: 10.1111/j.1476-5381.1987.tb11198.x
Harrison NL, Simmonds MA. Modulation of the GABA receptor complex by a steroid anaesthetic. Brain Res. 1984;323:287–92.
pubmed: 6098342
doi: 10.1016/0006-8993(84)90299-3
Gyermek L, Soyka LF. Steroid anaesthetics. Anesthesiology. 1975;42:331–44.
pubmed: 236704
doi: 10.1097/00000542-197503000-00017
Radford SG, Lockyear JA, Simpson PJ. Immunological aspects of adverse reactions to althesin. Br J Anaesth. 1982;54:859–63.
pubmed: 7104135
doi: 10.1093/bja/54.8.859
Stella VJ, He Q. Cyclodextrins. Toxicol Pathol. 2008;36:30–42.
pubmed: 18337219
doi: 10.1177/0192623307310945
Goodchild CS, Serrao JM, Kolosov A, Boyd BJ. Alphaxolone reformulation: a water-soluble intravenous anaesthetic preparation in sulfobutyl-ether-b-cyclodextrin. Anesth Analg. 2015;120:1025–31.
pubmed: 25517195
doi: 10.1213/ANE.0000000000000559
Monagle J, Siu L, Worrell J, et al. A phase 1c trial comparing the efficacy and safety of a new aqueous formulation of alphaxalone with propofol/. Anesth Analg. 2015;121(4):914–24.
pubmed: 26226029
pmcid: 4564024
doi: 10.1213/ANE.0000000000000856
Maksimovic S, Useinovic N, Quillinan N, Covey DF, Todorovic SM, Jevtovic-Todorovic V. General anesthesia and the young brain: the importance of novel strategies with alternate mechanisms of action. Int J Mol Sci. 2022;23(3):1889. https://doi.org/10.3390/ijms23031889 .
doi: 10.3390/ijms23031889
pubmed: 35163810
pmcid: 8836828
Huttenlocher PR, Arun SD. Regional differences in synaptogenesis in human cerebral cortex. J Comp Neurol. 1997;387:167–78.
pubmed: 9336221
doi: 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z
FDA Review results in newwarnings about using general anesthetics and sedation drugs in young children and pregnant women. 2016. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communicationfda-review-results-new-warnings-about-using-general-anesthetics-and . Accessed 20 Jan 2024.
Atluri N, Joksimovic SM, Oklopcic A, Milanovic D, Klawitter J, Eggan P, Krishnan K, Covey DF, Todorovic SM, Jevtovic-Todorovic V. A neurosteroid analogue with T-type calcium channel blocking properties is an effective hypnotic, but isnot harmful to neonatal rat brain. Br J Anaesth. 2018;120:768–78.
pubmed: 29576117
pmcid: 6200096
doi: 10.1016/j.bja.2017.12.039
Tesic V, Joksimovic SM, Quillinan N, Krishnan K, Covey DF, Todorovic SM, Jevtovic-Todorovic V. Neuroactive steroids alphaxalone and CDNC24 are effective hypnotics and potentiators of GABAA currents, but are not neurotoxic to the developingrat brain. Br J Anaesth. 2020;124:603–13.
pubmed: 32151384
pmcid: 7222221
doi: 10.1016/j.bja.2020.01.013